JP2017514905A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514905A5
JP2017514905A5 JP2017509591A JP2017509591A JP2017514905A5 JP 2017514905 A5 JP2017514905 A5 JP 2017514905A5 JP 2017509591 A JP2017509591 A JP 2017509591A JP 2017509591 A JP2017509591 A JP 2017509591A JP 2017514905 A5 JP2017514905 A5 JP 2017514905A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
linker
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017509591A
Other languages
English (en)
Japanese (ja)
Other versions
JP6629837B2 (ja
JP2017514905A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/027791 external-priority patent/WO2015168019A2/en
Publication of JP2017514905A publication Critical patent/JP2017514905A/ja
Publication of JP2017514905A5 publication Critical patent/JP2017514905A5/ja
Application granted granted Critical
Publication of JP6629837B2 publication Critical patent/JP6629837B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017509591A 2014-04-30 2015-04-27 抗ptk7抗体−薬物コンジュゲート Expired - Fee Related JP6629837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986520P 2014-04-30 2014-04-30
US61/986,520 2014-04-30
PCT/US2015/027791 WO2015168019A2 (en) 2014-04-30 2015-04-27 Anti-ptk7 antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019220041A Division JP2020055846A (ja) 2014-04-30 2019-12-05 抗ptk7抗体−薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2017514905A JP2017514905A (ja) 2017-06-08
JP2017514905A5 true JP2017514905A5 (https=) 2018-08-30
JP6629837B2 JP6629837B2 (ja) 2020-01-15

Family

ID=54249561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017509591A Expired - Fee Related JP6629837B2 (ja) 2014-04-30 2015-04-27 抗ptk7抗体−薬物コンジュゲート
JP2019220041A Pending JP2020055846A (ja) 2014-04-30 2019-12-05 抗ptk7抗体−薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019220041A Pending JP2020055846A (ja) 2014-04-30 2019-12-05 抗ptk7抗体−薬物コンジュゲート

Country Status (30)

Country Link
US (2) US9777070B2 (https=)
EP (2) EP3137114B8 (https=)
JP (2) JP6629837B2 (https=)
KR (2) KR102238032B1 (https=)
CN (1) CN106659801B (https=)
AR (1) AR100215A1 (https=)
AU (2) AU2015253422B2 (https=)
BR (1) BR112016025291A2 (https=)
CA (1) CA2947148C (https=)
CY (1) CY1124131T1 (https=)
DK (1) DK3137114T3 (https=)
ES (1) ES2856927T3 (https=)
HR (1) HRP20210292T1 (https=)
HU (1) HUE053287T2 (https=)
IL (1) IL248475B (https=)
LT (1) LT3137114T (https=)
MX (1) MX375284B (https=)
NZ (1) NZ725480A (https=)
PE (1) PE20170517A1 (https=)
PH (1) PH12016502142B1 (https=)
PL (1) PL3137114T3 (https=)
PT (1) PT3137114T (https=)
RS (1) RS61516B1 (https=)
RU (1) RU2708075C2 (https=)
SG (2) SG11201608953WA (https=)
SI (1) SI3137114T1 (https=)
SM (1) SMT202100146T1 (https=)
TW (1) TWI679022B (https=)
WO (1) WO2015168019A2 (https=)
ZA (1) ZA201607385B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
HUE029672T2 (en) * 2014-01-10 2017-03-28 Synthon Biopharmaceuticals Bv Duokarmicin-ADCs for use in the treatment of endometrial cancer
MX2017004580A (es) * 2014-10-10 2017-06-27 Pfizer Combinaciones de auristatina sinergica.
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
JP7708662B2 (ja) * 2018-10-24 2025-07-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
US20230181750A1 (en) * 2020-05-06 2023-06-15 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
TW202208412A (zh) 2020-05-06 2022-03-01 瑞士商Crispr治療公司 對酪胺酸蛋白激酶樣7(ptk7)特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞
WO2021231762A2 (en) * 2020-05-13 2021-11-18 The Trustees Of Indiana University Combination therapy for the treatment of tnbc with a pi3k pathway inhibitor that targets pi3kdelta and pi3kgamma tnbc
WO2021247805A1 (en) * 2020-06-05 2021-12-09 The Johns Hopkins University Humanized antibodies directed against kcnk9
US12605433B2 (en) 2020-07-16 2026-04-21 Uif (University Industry Foundation), Yonsei University Antibody specifically binding to PTK7 and use thereof
CN112394166B (zh) * 2020-11-09 2024-06-25 广东希格生物科技有限公司 六氟磷酸盐在制备抑制elisa反应基质效应的制剂中的应用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
CN114028579B (zh) * 2021-12-01 2023-09-05 中南大学湘雅三医院 核酸适配体-药物结合物PTK7-GEMs在制备治疗膀胱癌药物中的应用
IL315366A (en) 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
JP2025528015A (ja) * 2022-08-19 2025-08-26 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド Ptk7結合タンパク質及びその用途
US20260078201A1 (en) * 2022-09-06 2026-03-19 Uif (University Industry Foundation), Yonsei University Anti-ptk7 antibody, and use thereof
AU2023360382A1 (en) * 2022-10-14 2025-04-24 Kyoto University Antibody and use thereof
KR20250084919A (ko) 2022-10-14 2025-06-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 인간 ptk7에 결합하는 항체-약물 접합체 및 그의 제조 및 사용 방법
CN115990264A (zh) * 2022-12-21 2023-04-21 中国科学院基础医学与肿瘤研究所(筹) 一种ptk7靶向核酸适体偶联药物
JP2026508145A (ja) 2023-02-09 2026-03-10 ビーワン メディシンズ ワン ゲーエムベーハー 自己安定化リンカーコンジュゲート
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
TW202500198A (zh) 2023-06-29 2025-01-01 瑞士商百濟神州瑞士有限責任公司 生物活性偶聯物、其製備方法及用途
CN121568721A (zh) 2023-06-29 2026-02-24 广州百济神州生物制药有限公司 生物活性缀合物、其制备方法和其用途
WO2025040588A1 (en) * 2023-08-18 2025-02-27 Oncoinvent As Monoclonal anti-ptk7 antibodies and derivatives
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025195180A1 (zh) * 2024-03-20 2025-09-25 上海华奥泰生物药业股份有限公司 Ptk7抗原结合蛋白及其应用
WO2025231037A1 (en) 2024-04-30 2025-11-06 Solve Therapeutics, Inc. Conjugates of anti-ptk7 antibodies
US12534529B1 (en) 2024-11-19 2026-01-27 Solve Therapeutics, Inc. PTK7-binding proteins
CN120501877A (zh) * 2024-11-20 2025-08-19 中国科学院杭州医学研究所 一种ptk7靶向核酸适体偶联药物及其新应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5952329A (en) 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1158997A2 (en) 1999-03-09 2001-12-05 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7498029B2 (en) 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2003217930A1 (en) 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
GB0219776D0 (en) 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
DK1633784T3 (da) 2003-05-09 2011-10-24 Diadexus Inc OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
DK1675961T3 (da) 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US8222253B2 (en) 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US20090304721A1 (en) 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
WO2007080457A2 (en) 2005-12-30 2007-07-19 Institut Gustave Roussy Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
TW200806685A (en) 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
EP2032694A4 (en) 2006-06-06 2010-09-15 Univ Tennessee Res Foundation COMPOSITIONS ENRICHED WITH NEOPLASTIC STEM CELLS AND THESE COMPREHENSIVE METHODS
ES2646545T3 (es) 2006-09-07 2017-12-14 Arthur E. Frankel Métodos y composiciones basadas en conjugados de toxina diftérica-interleucina-3
PE20090305A1 (es) 2007-05-22 2009-03-15 Wyeth Corp Proceso mejorado para la elaboracion de hidrazidas
WO2008149803A1 (ja) 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
WO2009012357A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
JP2011505146A (ja) 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー タンパク質チロシンキナーゼ7(ptk7)を対象とするモノクローナル抗体−パートナー分子複合体
WO2009116764A2 (ko) 2008-03-17 2009-09-24 연세대학교 산학협력단 Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
KR101123130B1 (ko) 2008-03-17 2012-03-30 연세대학교 산학협력단 Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
EP2207803B1 (en) 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies
KR20110108390A (ko) 2009-01-12 2011-10-05 신텔렉트 인코포레이티드 레이저로 매개된 박막 절개 및 세포 군체의 이동
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2611463A2 (en) 2010-09-03 2013-07-10 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
AU2012335205A1 (en) * 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use

Similar Documents

Publication Publication Date Title
JP2017514905A5 (https=)
RU2016143119A (ru) Конъюгаты анти-ртк7 антитело-лекарственное средство
US20260062423A1 (en) Biologically active molecules, conjugates thereof, and therapeutic uses
CA3213625A1 (en) Selective drug release from internalized conjugates of biologically active compounds
AU2023234594A1 (en) Camptothecin conjugates
JP7244987B2 (ja) 多剤抗体薬物コンジュゲート
US10562977B2 (en) Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
ES2983109T3 (es) Conjugados enlazadores autoestabilizantes
RU2610336C2 (ru) Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
US20230173093A1 (en) Charge variant linkers
ES2826398T3 (es) Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
AU2018241840A1 (en) HDAC inhibitors-based antibody drug conjugates (ADCs) and use in therapy
JP2018537975A5 (https=)
RU2016119491A (ru) Конъюгаты антитела к efna4 с лекарственным средством
JP2016540826A5 (https=)
Shao et al. Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C
MX2022007721A (es) Tratamiento con conjugados de farmaco-anticuerpo her2 especifico del sitio.
US12419964B2 (en) Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
JPWO2020065408A5 (https=)
JPWO2022261124A5 (https=)
RU2021131990A (ru) Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2